To date, selective blockade of Toll-like receptor (TLR) signalling has been developed as a new approach for treatment for many inflammatory diseases. As b-D-mannuronic acid (M2000) has been known as an anti-inflammatory molecule in several experimental models, we investigated the antagonistic effects of M2000 on TLR2 and TLR4 downstream signalling transduction pathway in human embryonic kidney (HEK) 293 cell lines overexpressing TLR2/CD14 and the TLR4/MD2/CD14 complex, respectively. M2000 effectively inhibited mRNA expression of MyD88 and p65, major subunit of nuclear factor-jB, in HEK293 cells stimulated by lipoteichoic acid (LTA, a TLR2 agonist) and lipopolysaccharide (LPS, a TLR4 agonist) with no evidence of cytotoxicity. In addition, M2000 also suppressed LTA and LPS-induced production of TNF-a and IL-6 inflammatory cytokines in these cells. Furthermore, the results revealed that M2000 had no significant effect on Tollip mRNA expression as a negative regulator of TLR signalling in aforesaid cells. Overall, these data point to M2000 inhibitory effect on Toll-like receptor (TLR) 2, 4 signalling in HEK293 cells. This information might provide new insights into the possible roles of this small drug in order to introduce it as a TLR signalling pathway inhibitor. However, more studies are needed to confirm b-D-mannuronic acid antagonistic effects including the effects of M2000 on peritoneal isolated macrophages and also on blood cells in patients with inflammatory diseases such as ankylosing spondylitis.
Introduction
Toll-like receptors (TLRs) are a family of type 1 transmembrane proteins which are classified based on homology of cytoplasmic portion with that of the interleukin-1 (IL-1 R) receptor family, called the Toll/IL1-R (TIR) domain [1] . It is estimated that there are 13 members of TLR family in mammals. Ten of these receptors, containing TLR1-10, have been recognized in human and mouse [2] . Toll-like receptors can be categorized into two subfamilies based on their cellular localization. Toll-like receptors (TLR1, 2, 4, 5, 6 and 10) are expressed at the plasma membrane, whereas TLR3, 7, 8 and 9 are located in endosomal or lysosomal compartments and endoplasmic reticulum (ER) [3] . Besides, several studies suggested that TLR9 was found not only in the cytoplasm, but also on the cell membrane [4, 5] . These receptors are expressed in immune and non-immune cells including monocytes, macrophages, dendritic cells, neutrophils, B cells, T cells, NK cells, mast cells, keratinocytes, and mucosal epithelial and endothelial cells [6] . In addition, the presence of functional Toll-like receptors in platelets and synovial fibroblast has also been confirmed [7, 8] . The various TLRs recognize invading pathogens by specific patterns of microbial components, which is known pathogen-associated molecular patterns (PAMPs). PAMPs structures, including LPS, LTA and peptidoglycan, are conserved on various micro-organisms [3] . Toll-like receptors also are able to recognize endogenous molecules released from stressed or dying cells including damage-associated molecular patterns such as hyaluronan, heat-shock proteins and fibronectin that promoted inflammatory pathway [9] . TLR2 is able to detect a variety of microbial products, such as lipopeptides, lipoproteins, peptidoglycan, lipoteichoic acid, b-glucan through heterodimers formation with others TLRs [10] . TLR1/TLR2 and TLR2/TLR6 heterodimers are required to respond to the triacylated lipopeptide and peptidoglycan, respectively [10, 11] . Also, TLR4 is the main recognition receptor of LPS, a gram-negative bacterial cell wall component. Lipopolysaccharide (LPS) is recognized by four molecules including LPS binding protein (LBP), CD14, myeloid differentiation protein-2 (MD2) and TLR4. MD2 is a molecule which binds to the extracellular part of TLR4 and increases response to LPS [12, 13] . After binding respective ligands, TLRs activate MyD88-dependent and MyD88-independent signalling pathways that lead to recruitment adaptor proteins including myeloid differentiation factor 88 (MyD88), TIR-associated protein (TIRAP), TIR domaincontaining adaptor protein-including INF-b (Trif) and TRIF-related adaptor molecule (TRAM) [14] . MyD88 interacts with TIR domain of TLRs and then interacts with IL-1R-associated kinase 1 (IRAK1) and IRAK4 [15] . They cause to activate NF-kB and AP-1 transcription factors that regulate the expression of inflammatory cytokine genes such as TNF-b, IL-1, IL-6 and IL-12 [14] . The negative regulation of TLR signalling is essential for terminating the inflammatory responses and a number of molecules that contribute to negative control of TLR signalling such as MyD88, IRAK-M, SOCS1 and Tollip. Tollip as an inhibitory protein in TLR2 and TLR4 signalling pathway is associated with IRAK-1 for reducing IRAK-1 autophosphorylation levels and inhibition of its kinase activity [16, 17] . Toll-like receptors especially TLR2, 4 are involved in many autoimmune disorders and inflammatory diseases, and TLR2, TLR4-single nucleotide polymorphism are associated with particular diseases. They are related to a range of diseases, including rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis, multiple sclerosis, systemic lupus erythematosus and type 1 diabetes [18, 19] . Therefore, the studies suggest that the use of TLR2 and TLR4 antagonists, as well as their signal transduction inhibitors could be considered in treatment of these diseases. It has also been found that antagonists act through various mechanisms in TLR2 and TLR4 signalling including inhibition of interaction between TLR and its ligand, inhibition of linking between TLR and its adaptor molecules and suppression of enzymatic activity of downstream factors. For example, TAK-242 and Eritoran are the main antagonists of TLR4 that suppress LPS-induced inflammation by binding to TLR4-MD2 complex and TIR domain of TLR4, respectively [20, 21] .
M2000 (b-D-mannuronic Acid) molecule is an antiinflammatory drug with immunosuppressive property patented (DE-10247073) belongs to NSAID group. A bulk of studies has shown the immunosuppressive properties of M2000 in several experimental models such as adjuvant induced arthritis [22] , experimental autoimmune encephalomyelitis (EAE) [23] , nephrotic syndrome and glomerulonephritis [24, 25] . Although previous works have been indicated anti-inflammatory action of M2000, so far no investigation has been carried out about its effects on TLRs. Therefore, based on in vivo results and regarding the important role of TLR2, 4 in inflammation and autoimmune diseases, in this research, our aim was to study the pharmacological effect of M2000, a small molecule-derived alginate polysaccharide, on TLR2 and TLR4 downstream signalling transduction pathway in human embryonic kidney (HEK) 293 cell line in vitro.
Materials and methods
Cells and materials. M2000 or b-D-mannuronic acid was prepared at Tehran University of Medical Science. Drug purity was confirmed by Fourier Transform Infrared (FT-IR) and Carbon-13 Nuclear Magnetic Resonance (C-NMR) spectroscopy [26] . Lipoteichoic acid (LTA; Staphylococcus aureus) and 3-4, 5-(dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) were obtained from Sigma Chemical Co (St. Louis, MO, USA). The absence of bacterial endotoxins contamination in LTA agonist LTA agonist was assayed using the Limulus amebocyte lysate test. Lipopolysaccharide from Escherichia coli O111:B4 purified by gel-filtration chromatography was purchased from sigma. OxPAPC as TLR2 and 4 antagonist was purchased from Invivogen (San Diego, CA, USA). HEK-Blue h TLR2 cells stably expressing human TLR2/CD14 and HEK293-Blue-hTLR4-CD14-MD2 cells overexpressing human TLR4/MD2/CD14 were prepared from NCBI (National Cell Bank of Iran at Pasteur Institute).
HEK-Blue-Null 1 (as control HEK-Blue h TLR2) and HEK-Blue-Null 2 (as control HEK-Blue h TLR4) cells without any expression of TLR2 and TLR4 were also obtained from NCBI.
Cell culture. Initially, HEK-Blue h TLR2, HEK-Blue h TLR4, HEK-Blue-Null1 and HEK-Null 2 cells were cultured in RPMI1640 and complete growth medium containing 10% heat-inactivated foetal bovine serum, 2 mM glutamine, 1 mM sodium pyruvate, antibiotics including 100 units/ml penicillin, 100 lg/ml streptomycin (Gibco, Life Technologies, Grand Island, NY, USA). The cultures were grown at 37°C under a humidified atmosphere in the presence of 5% carbon dioxide (CO 2 ) until reaching 80% confluency. The medium was changed 3 times a week. Then, HEK-Blue hTLR2 and HEK-Blue h TLR4 were divided into seven treatment groups.
Cell viability test. Cell viability and cytotoxicity studies of M2000 were performed by MTT assay. The cell counting was conducted using Trypan Blue and HEKBlue h TLR4. Cells were then seeded (1 9 10 4 cells per well) in 96-well plates. 24 h after seeding, twofold dilutions of b-D-mannuronic acid (at concentration of 62.5-1000 lg/ml) were added to cells and incubated overnight. Then, 100 ll of MTT solution (0.5 mg/ml) was added into each well and incubated for 4 h. The incubation was stopped by the addition of dimethylsulfoxide dissolved in formazan. Finally, absorbance was measured using a microplate reader at 570 nm.
Treatment of cells. HEK-Blue h TLR2, HEK-Blue h TLR4, HEK-Blue-Null 1 and HEK-Blue-Null 2 were Ó 2016 The Foundation for the Scandinavian Journal of Immunology seeded at a density of 5 9 10 5 cells in 1000 ll per well of 6-well plates in RPMI medium, followed by an incubation for 24 h. In first, the HEK-Blue h TLR-2/-4 cells were pretreated with M2000 low dose (5 lg/well) and high dose (25 lg/well) for 4 h and were then incubated in the presence or absence of TLR2/TLR4 ligands [TLR2 (LTA), TLR4 (LPS)]. Based on previous studies, LTA at concentration of 10 lg/ml [27] and LPS at concentration of 1 lg/ml [28] were used. Also cells were stimulated with LPS and LTA without of M2000 (5 and 25 lg/well) as control. Moreover, cells were treated with OxPAPC (30 lg/ml) as antagonist (for TLR2/TLR4 cells) alone along with blank medium (untreated; negative control) and incubated for 24 h at 37°C in the presence of 5% CO 2 . Control HEK cells (HEK-Null 1, 2) were incubated with LTA, LPS and M2000 (5, 25 lg/well) to confirm our results. At the end of incubation, collected supernatants were stored at À80°C until next use. The levels of secreted TNF-a and IL-6 cytokines in the supernatant were measured using ELISA kit according to the manufacturer ' s instructions. RNA extraction and reverse transcription (RT-PCR). Total RNA was isolated from untreated and treated cells using ABI Systems (Applied Biosystems, CA, USA) kit according to the manufacturer's protocol. The quality and concentration of isolated RNA were evaluated by gel agarose electrophoresis on the GelRed TM (Biotium, CA, USA) and UV spectrophotometry (NanoDrop ND1000) using the A260/280 and 260/230 nm ratio. cDNA was synthesized on RNA (1 lg) using cDNA reverse transcription kit (ABI Systems). Afterwards, PCR analysis and gel agarose electrophoresis were performed to confirm the quality of synthesized cDNA and primers.
Amplification of MyD88, the NF-kB p65 subunit and Tollip genes from the cDNA was performed using genespecific primers. Table 1 represents a list of primer sequences that have been used in our study.
For further investigation, at the end of each PCR, PCR products were then subjected to electrophoresis in 3% agarose gel and the DNA bands were visualized with ethidium bromide and observed under UV.
Quantitative real-time PCR. Quantitative real-time PCR was performed using SYBR Premix (ABI System) with specific primer (Table 1) . In brief, 20 ll of real-time PCR reaction included 1 ll genomic template DNA, 10 ll SYBR Premix, 7 ll RNase Free-Water, 1 ll (100 nM) forward primer, 1 ll (100 nM) reverse primer. The following program was proceeded on the ABI StepOne Plus real-time PCR system (ABI System): one cycle of 95°C for 30 s followed by 40 cycles of 95°C for 5 s, 60°C for 30 s, and 60°C for 15 s. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping gene was used for normalization of amplification. The relative abundance of each gene was calculated using the 2
ÀDDCt method (Ct refers to the threshold value). Amplified products were analysed on 3% agarose gel electrophoresis to re-examine the size of PCR products. ELISA. Assessment of the amount of TNF-a and IL-6 cytokines was performed by enzyme-linked immunosorbent assay (ELISA kit; eBioscience, San Diego, CA, USA) according to the manufacturer's guidelines. The concentration range for standard curve was from 3.12 to 200 pg/ ml with test sensitivity of 2 pg/ml.
Statistical analysis. Data were analysed statistically using SPSS 16.0 software. (Inc, Chicago, IL, USA). The results were compared by analysis of variance (ANOVA) followed by Tukey's test, with the level of significance set at P < 0.05. The results were expressed as mean AE SD.
Results

Cytotoxicity measurement of M2000
Before further studies on the inhibitory effects of M2000, we evaluated its cytotoxicity using MTT assay. Several concentrations of M2000 were tested including, 62.5, 125, 250, 500 and 1000 lg/ml. The result of MTT assay indicated that M2000 at concentration up to 500 lg/ml had no apparent cytotoxicity effect on the HEK-Blue h TLR4 cells (Fig. 1) .
Effect of M2000 on expression of MyD88, NF-kB and Tollip
To determine whether the inhibitory effect of M2000 is linked with TLR signalling, we utilized quantitative realtime PCR to assay MyD88, NF-kB and Tollip mRNA expression in HEK-Blue h TLR2 and HEK-Blue h TLR4 cells.
Effect on MyD88
HEK-Blue h TLR2; After culturing these cells in RPMI1640 media overnight, cells were pretreated for (Fig. 2) . The statistical analyses revealed that difference between these groups and control (untreated cells) was significant (P value <0.05). The data also showed that stimulation with 10 lg/ml LTA augmented mRNA expression of MyD88, while the mRNA expression was reduced threefold and 52-fold in M2000 low dose and M2000 high dose, respectively, when this drug was added 4 h before LTA. HEK-Null 1 had no effect on MyD88 expression in response to LTA and M2000. (Fig. 2) . HEK-Blue h TLR4; The exposure of cells with M2000 indicated that the expression of MyD88 in HEK-Blue h TLR4 cell line was increased 2.5-fold in concentration of 5 lg/well in comparison with control group (P < 0.05), whereas the difference between high-dose M2000 and untreated cells was not significant (P > 0.05). Also, we evaluated the suppressive effect of M2000 on mRNA expression of MyD88 in the stimulated cells with LPS. We found M2000 (both at 5 and 25 lg/well) diminished MyD88 expression in comparison with LPS only (P < 0.05). Moreover, OxPAPC as antagonist had no significant effect on MyD88 expression. As expected, HEK-Blue-Null 2 did not show any alternation in MyD88 expression following exposure to TLR4 ligand (LPS) and M2000 (Fig. 3) .
Effect on NF-kB
HEK-Blue h TLR2; To further evaluate the inhibitory effect of M2000 on TLR2 signalling, mRNA expression of NFkB was measured using quantitative real-time PCR. As shown in Fig. 4 , after 24-h treatment by M2000, the mRNA expression of NF-kB in HEK-Blue h TLR2 cell lines was downregulated than unstimulated cells of MyD88 expression by M2000 antagonist in HEKBlue h TLR2 cell line. Cells were exposed to M2000 (5, 25 lg/well) with or without LTA (10 lg/ml) stimulation for 24 h. M2000 was added 4 h before LTA stimulation. Total RNA was isolated after 24 h for assessment of MyD88 expression levels. Expression levels were measured by quantitative real-time PCR. Data points are given as mean AE SD. The sign of * is indicator of significant statistical differentiation with control group. The sign of # is indicator of significant differentiation with LTA group. ML (mannuronic low dose), MH (mannuronic high dose), ML+LTA (adding ML, 4 h before LTA), MH+LTA (adding MH, 4 h before LTA). Figure 3 The Real-time PCR analysis for MyD88 mRNA expression in HEK-Blue h TLR4 cell line. Real-time PCR was performed on total RNA isolated from HEK293 h TLR4 cells that pretreated with M2000 (5, 25 lg/well) in the presence or absence of LPS (1 lg/ml). M2000 was pretreated 4 h before cells stimulation with LPS. Data are presented as mean AE SD. *P < 0.05, as compared with control group. #P < 0.05, as compared with LPS group. ML (mannuronic low dose), MH (mannuronic high dose), ML+LPS (adding ML, 4 h before LPS), MH+LPS (adding MH, 4 h before LPS).
Ó 2016 The Foundation for the Scandinavian Journal of Immunology (P < 0.05). On the other hand, our findings indicated that cells pretreatment for 4 h with M2000 (in both low and high dose) prior to stimulation with LTA was significantly attenuated NF-kB expression than LTA alone. Similar to MyD88 gene, OxPAPC had no effect on expression of NFkB. Also, NF-kB expression in HEK-Null 1 cells was similar to untreated cells without alternation. (Fig. 4) .
HEK-Blue h TLR4; We tested the effect of M2000 on expression of NF-kB in HEK-Blue TLR4. Similar to the result obtained of MyD88 expression, M2000 at 5 lg/well concentration was raised mRNA expression of NF-kB, while at 25 lg/well was not changed its expression compared to control cells. (Fig. 5) On the other hand, challenged cells with M2000 before LPS showed a decreased NF-kB expression in comparison with stimulated cells with LPS (P < 0.05). Moreover, the difference between negative control (untreated cells) and OxPAPC groups was insignificant (P > 0.05). There was no NF-kB expression in the presence of LPS and M2000 in HEK-Null 2 cells (Fig. 5) .
Effect on Tollip
Tollip is identified as inhibitory protein that is able to interact with IRAK1 in TLR2, 4 signalling pathway. Tollip is constitutively expressed in resting cells, and Tollip/IRAK1 complexes are present in cytoplasm prior to cell stimulation [16] .
HEK-Blue h TLR2; M2000 at 5 and 25 lg/well doses had no change on Tollip expression than control group (P > 0.05). However, the expression of Tollip in M Low dose + LTA and M High dose + LTA groups were insignificantly altered in comparison with LTA group (P > 0.05), data not shown.
HEK-Blue h TLR4; Our complementary results indicated that M2000 affected on the expression of Tollip in HEK-Blue h TLR4 affected similar to those at which it affected on the expression of Tollip in HEK-Blue h TLR2 (P > 0.05), data not shown.
Effect of M2000 on TNF-a and IL-6
HEK-Blue h TLR2; Regarding M2000 had an effect on cytosolic targets of TLR2 and TLR4, we tested whether M2000 is able to decrease the production of TNF-a and IL-6 as inflammatory cytokines. Cells were treated with M2000 with or without LTA for 24 h, and cell supernatants were collected for evaluation of TNF-a and IL-6 cytokines using ELISA. As shown in Fig. 6 , we detected TNF-a and IL-6 production from HEK-Blue h TLR2 cells following stimulation with LTA. However TNF-a and IL-6 showed a significant decrease in all groups including M low dose, M high dose, M low dose + LTA, M high dose + LTA, OxPAPC and negative control.
HEK-Blue h TLR4; The levels of TNF-a and IL-6 cytokines in HEK-Blue h TLR4 cells treated with LPS (1 lg/ml) were significantly increased. However in pretreated cells with M2000 and subsequent LPS, the increase in these cytokines was lower in comparison with LPStreated cells (P > 0.05). Although there was a significant increase of these cytokines in cells treated with 5 lg/well M2000, the changes between untreated cells and pretreated cells with 25 lg/well M2000 and subsequent LPS were not notable (P > 0.05). Furthermore, the concentration of Figure 4 Inhibitory effect of M2000 on LTA-induced expression of NFkB p65 transcription factor in HEK-Blue h TLR2 cell line. HEK-Blue h TLR4 cells were incubated with the varying concentration of M2000 (5, 25 lg/well) for 4 h prior to addition of LTA at 10 lg/ml. Also cells treated with M2000 and LTA alone. After 24 h, the total RNA was examined for NF-kB p65 expression by real-time PCR. Results are as mean AE SD. *P < 0.05 versus control group. #P < 0.05, versus LTA group. ML (mannuronic low dose), MH (mannuronic high dose), ML+LTA (adding ML, 4 h before LTA), MH+LTA (adding MH, 4 h before LTA). Figure 5 Inhibitory effect of M2000 on NF-kB p65 gene expression in HEK-Blue h TLR4 cell line. HEK-Blue h TLR4 cells incubated with M2000 (5, 25 lg/well) for 4 h and further incubated with LPS (1 lg/ml) for additional 24 h. using quantitative real-time PCR analysis the levels of NF-kB p65 expression were assayed. Data points are given as mean AE SD. *P < 0.05 indicating significant differentiation with control group. #P < 0.05 indicating significant differentiation with LPS group. ML (mannuronic low dose), MH (mannuronic high dose), ML+LPS (adding ML, 4 h before LPS), MH+LPS (adding MH, 4 h before LPS).
TNF-a and IL-6 in other groups was not significantly increased. Also release of TNF-a and IL-6 was not observed after treatment of HEK-Blue-Null 1,2 cells with LTA, LPS and M2000 (5, 25 lg/well; Fig. 7 ).
Discussion
At first, M2000 was identified as an anti-inflammatory molecule with therapeutic effect in nephrotic syndrome experimental model [24] . Previous findings had shown that M2000 leads to a significant decrease in paw oedema and histopathological parameters in arthritic rats [22] and also, immunosuppressive efficacy on lymph node cell proliferation in the EAE model [23] . Despite these studies about therapeutic effects of M2000 in animal models, the mechanism of M2000 as an anti-inflammatory agent is still unclear. Regarding the direct and indirect links of TLR2 and TLR4 and their cytosolic targets with autoimmune and inflammatory diseases, we evaluated whether anti-inflammatory properties of M2000 are able to affect on TLR2,4 signalling pathway.
In this study, we tested the effect of M2000 on TLR2-and TLR4-mediated inflammatory response. The signalling cascade was studied using the quantitative real-time PCR method and also determined the levels of TNF-a and IL-6 released by treated cells. Using HEK293-Blue TLR-2/-4 cells, a highly useful cell line for study TLRs signalling, M2000 was treated alone and also, before stimulation of LTA/LPS. First, we assessed the optimal concentration of M2000 that had no cytotoxicity. The cell viability was 100% at concentration of 62.5, 125, 250 lg/ml (6.25, 12.5, 25 lg/well) and 80% at 500 lg/ml (50 lg/well). Also our data show that MyD88 and NF-kB were downregulated following the exposure to M2000 (at 5 and 25 lg/well) alone in HEK-Blue h TLR2. We found that the expression of these genes were briefly increased after treatment with M2000 (5 lg/well) in HEK-Blue h TLR4 cell line, but higher concentration of M2000 (25 lg/well) had no significant effect on MyD88 and NF-kB expression compared to control group (untreated cells). These results suggest that M2000 probably binds directly to TLR4 at concentration 5 lg/well and, therefore, could block this receptor and also, lead to slight stimulation of TLR4. But unexpectedly, M2000 at 25 lg/well had no the stimulatory effect on TLR4. On the other hand, we found treatment with LPS (1 lg/ml) increased gene expression of NF-kB and MyD88 whereas pretreatment with M2000 before LPS significantly reduced expression of these genes, indicating that M2000 can likely bind to TLR4 and inhibit attachment of LPS to TLR4. Furthermore, previous studies have indicated that involvement of TLR2/4 and CD14 by alginate-derived mannuronic acid polymers and oligomers induced cytokine production in monocyte and HEK293 cell line [29, 30] . The immunostimulatory activity of alginate oligomers depends on molecular size, the content of mannuronate residues and molecular conformation [31, 32] . Regarding the relationship between structure and immunostimulatory activity of alginate oligomers, it seems likely that M2000, monomer composition of sodium alginate, can act as a carbohydrate antagonist for TLR2, 4. Currently, various drugs have been developed to target TLRs binding with their ligands or downstream molecules such as MyD88 and NF-kB but directly linked TLR antagonists are less developed. Slivka and et al. introduced MD-I (a small peptide antagonist of TLR4 signalling) that linked to TLR4 and can block interaction between TLR4 and MD2 [33] . The inhibitory potential of M2000 is not limited to TLR4. The analysis of the TLR2 blocking activity similarly showed that pretreatment with M2000 (in both 5 and 25) leads to a significant reduction in MyD88 Figure 6 The effect of M2000 antagonist on the TNF-a and IL-6 cytokine production in HEK-Blue h TLR2 cell line. HEK293 cells were pretreated with various concentrations of M2000 for 4 h and then stimulated with LTA for 24 h. Cell supernatant was used for evaluation of IL-6 cytokine levels using ELISA. Data points are given as mean AE SD. # P < 0.05, versus LTA group. ML (mannuronate low dose), MH (mannuronate high dose), ML+LTA (mannuronate low dose along with LTA), MH+LTA (mannuronate high dose along with LTA). Figure 7 Anti-inflammatory action of M2000 on the production of TNFa and IL-6 cytokines in HEK-Blue h TLR4 cell line. The production of TNF-a and IL-6 was quantified by ELISA following pretreatment of HEK293 cells with varying concentrations (5, 25 lg/well) of M2000 or M2000 (5, 25 lg/well) + LPS (1 lg/ml) after 24 h. Values in graphs represent mean AE SD. * P < 0.05, as compared with control group. # P < 0.05, as compared with LPS group. ML (mannuronate low dose), MH (mannuronat high dose), ML+LPS (mannuronate low dose along with LPS), MH+LPS (mannuronate high dose along with LPS).
Ó 2016 The Foundation for the Scandinavian Journal of Immunology and NF-kB expression in HEK-TLR2 cells stimulated with LTA (10 lg/ml) in a dose-dependent manner.
The Tollip protein has been suggested to be involved in inhibition of TLR2-and TLR4-mediated NF-kB activation [16, 17] . Hence, we postulated that M2000 might augment the expression of Tollip as a negative regulator of TLR2, 4 signalling. However, in the present study, M2000 did not alter the gene expression of Tollip in HEK 293 cells expressing TLR2 or TLR4 along with their accessory proteins suggesting that Tollip gene returned to basal levels after 24 h of stimulation. However, the molecular mechanism of Tollip exactly is not identified and the function of it in inhibiting production of TNF-a and IL-6 depended on low and high doses of LPS [17] . Therefore, further studies will be required to evaluate the effect of M2000 on Tollip and other inhibitory molecules at different times and various concentrations of M2000 and TLR2, 4 ligands.
In order to confirm the probable anti-inflammatory effects of M2000, we also studied the ability of TLR2, 4 ligands on TNF-a and IL-6 cytokine production in the presence of M2000, at two different doses. Our data revealed that M2000 suppresses TLR2-and TLR4-mediated TNF-a and IL-6 production in HEK293-stimulated cells.
Based on brief results here, for the first time we showed that M2000, a small molecule with carbohydrate structure, can probably block the TLR2, 4 signalling pathway but have not revealed how M2000 blocks the mentioned signalling.
It is important to note that limited reports of carbohydrate structure antagonists have been documented. Mani and Kalluri have shown RSCL-0409 is first of carbohydrate-based antagonist that could inhibit TNF-a production and NF-kB activation in THP-1 cells when were stimulated with Pam3ck4 (via TLR2) or LPS (via TLR4) ligand [34] .
Conclusion
With the presented data here, we indicated that b-Dmannuronic acid downregulated MyD88 and NF-kB mRNA levels together with TNF-a and IL-6 cytokine production levels in HEK-Blue h TLR2 and HEK-Blue h TLR4 cell line in vitro. This inhibitory effect is exerted via the MyD88-dependent pathway. It needs to be identified the direct target of M2000. With these data, M2000 acts as an inhibitor of TLR2, 4 signalling. In this way, M2000 blocks signalling adaptor protein and its related transcription factor. However, more studies are needed to confirm b-D-mannuronic acid antagonistic effects including the effects of M2000 on peritoneal isolated macrophages and also on blood cells in patients with inflammatory diseases such as ankylosing spondylitis. Investigations are continued to an efficient route to clarify M2000 specific target molecule.
